Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kuur Therapeutics

Request full access

Manufactures cellular immunotherapeutics in order to treat cancer and infectious diseases

Houston, United StatesFounded 2005Biotech & Life Sciences

About Kuur Therapeutics

Kuur Therapeutics is a pioneering biotech startup focused on revolutionizing cancer treatment through advanced cell therapy. The company specializes in developing engineered CAR NKT cell therapies, which are designed to target and destroy cancer cells. CAR stands for Chimeric Antigen Receptor, a technology that modifies immune cells to better recognize and attack cancer. NKT cells, or Natural Killer T cells, are a unique subset of immune cells known for their ability to kill cancer cells. Kuur Therapeutics operates in the highly specialized field of immunotherapy, which involves using the body's own immune system to fight diseases like cancer. The company serves patients suffering from both hematological (blood-related) and solid tumors. Their therapies are "off the shelf," meaning they are readily available and do not require customization for each patient, which can significantly reduce treatment time and costs. The business model of Kuur Therapeutics revolves around research, development, and commercialization of these innovative therapies. They generate revenue through licensing agreements and partnerships with other biotech firms and medical institutions. By collaborating with renowned entities like Baylor College of Medicine and Texas Hospital, Kuur Therapeutics leverages global expertise to advance their research and bring their products to market. Kuur Therapeutics has already made significant strides, including dosing the first patients with their allogeneic (donor-derived) CAR NKT cell therapy and publishing promising interim Phase 1 data. The company is actively seeking further licensing and partnership opportunities to expand the therapeutic possibilities of their NKT cell immunotherapy products. In summary, Kuur Therapeutics is at the forefront of cancer treatment innovation, offering a unique and potentially transformative approach to immunotherapy.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
10
Open positions
None listed
Dealroom signal
80.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, UKSU, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Jul 2016
Capital deployed
—
Preferred round
ACQUISITION

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing May 2021 $75M $185M Athenex ↗
FundingOther financing Jan 2021 $0 — Salica Investments —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Kuur Therapeutics website traffic

Latest recorded traffic for Kuur Therapeutics is 0 monthly website visits. Kuur Therapeutics's team grew 11.1% over the past year.

Latest monthly visits0 1-year team growth+11.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Kuur Therapeutics in the Houston ecosystem

Live from Dealroom

The Kuur Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Cancer Prevention and Research Institute of Texas (CPRIT)

Series A3 investors entered at this stage

  • Wellcome Trust
  • Imperial Innovations
  • Woodford Investment Management

Series B and later3 investors entered at this stage

  • Invesco
  • Invesco Perpetual
  • Touchstone Innovations

Other known investors4 additional known investors

  • Athenex
  • College of Medicine and Integrated Health
  • Imperial College London
  • Salica Investments
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Houston HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kuur Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kuur Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.